CBD for Canine Epilepsy: Benefits, Safety, Dosing Strategy

**CBD for Canine Epilepsy: A Pioneering Study Explores Benefits, Safety, and a New Dosing Strategy**

The management of drug-resistant epilepsy in dogs represents a significant challenge for veterinarians and a source of profound distress for pet owners. Conventional antiepileptic drugs (AEDs), while effective for many, can fail to control seizures in up to 30% of canine patients, often while introducing a burden of side effects that diminish quality of life. In the search for novel adjunctive therapies, cannabidiol (CBD)—a non-psychoactive compound derived from hemp—has surged into the spotlight due to its renowned anti-convulsant and neuroprotective properties in human medicine. However, robust evidence for its use in veterinary neurology has been sparse and sometimes contradictory. A groundbreaking 2024 pilot study from researchers at Kasetsart University in Thailand has now provided the first controlled evidence from Asia, pioneering a unique, careful dosing strategy that may revolutionize how we approach this promising treatment.

—

### **Key Takeaways**
* **Significant Seizure Reduction:** Over 60% of dogs with refractory epilepsy experienced a ≥50% drop in seizure frequency when CBD was added to their existing medication regimen.
* **Cluster Seizures Dramatically Decreased:** The study reported a statistically significant reduction in the number of dangerous seizure clusters, a major finding for patient safety.
* **Owner-Reported Life Quality Improved:** Pet owners perceived a clear benefit, reporting improved quality of life for their dogs during the CBD treatment period.
* **A Novel, “Start Low, Go Very Slow” Dosing Strategy:** Researchers employed a meticulous titration method, starting at an ultra-low dose (0.৫ mg/kg twice daily) to minimize side effects, which proved effective and safe.
* **Liver Enzyme Monitoring is Crucial:** A notable rise in alkaline phosphatase (ALP) levels underscores the critical need for regular veterinary monitoring, especially when CBD is used with other medications.
* **Proof of Concept for Refractory Cases:** This study provides the first structured evidence that adjunctive CBD therapy can be beneficial for dogs where standard AEDs alone are insufficient.

—

### **What the Research Found: A Deep Dive into the Kasetsart Study**

Published in *Animals* in December 2024, this prospective pilot study aimed to cut through the anecdote and establish evidence-based insights. The research team enrolled thirteen dogs diagnosed with idiopathic epilepsy that remained poorly controlled (experiencing at least two seizures monthly) despite treatment with at least two conventional AEDs.

Employing a single-arm, pretest-post-test design, dogs received oral CBD oil in addition to their existing medications. The dosing protocol was the study’s first innovative hallmark:
1. **Initial Dose:** 0.৫ mg/kg of body weight, administered twice daily.
2. **Titration Phase:** The dose was increased by 0.৫ mg/kg every two weeks *only if no adverse effects were observed*.
3. **Maintenance Dose:** The target maintenance dose was 2.৫ mg/kg BID, not all dogs reached this level due to individual tolerance.

The results, followed over a 12-week treatment period, were compelling:

* **Overall Seizure Frequency:** The median monthly seizure frequency decreased significantly, from 11 seizures (pre-treatment) to ৫ seizures (post-treatment)—a median reduction of over 50%.
* **Responder Rate:** Critically, 61.৫% of the dogs were classified as “responders,” achieving that golden standard of a ≥50% reduction in seizure frequency.
* **Seizure Clusters:** Perhaps the most impactful finding for patient safety was the dramatic and statistically significant decrease in the number of seizure clusters (multiple seizures within a 24-hour period).
* **Safety Profile:** Bloodwork and biochemistry profiles remained largely stable. However, a **significant increase in Alkaline Phosphatase (ALP)** was noted, an enzyme often associated with liver function বা biliary flow. This change, while not accompanied by other signs of liver damage, flags the importance of monitoring.
* **Quality of Life:** Through validated questionnaires, owners reported positive perceptions of the CBD treatment and noted improvements in their dogs’ overall quality of life.

—

### **What This Means for Veterinary Practice and Pet Owners**

This study does not present CBD as a magic bullet, but rather as a sophisticated, evidence-based tool. It moves the conversation beyond “Will CBD help my dog?” to **”How can we use CBD safely and effectively in my dog with difficult-to-control epilepsy?**

1. **A Paradigm Shift in Dosing:** The traditional “one-size-fits-all” approach is outdated. The Kasetsart protocol demonstrates that starting with an **exceedingly low dose and increasing with extreme patience** is key to unlocking benefits while avoiding gastrointestinal or sedative side effects that can occur with higher initial doses.
2. **Adjunctive, Not Replacement, Therapy:** CBD was used *with* traditional AEDs, not instead of them. This adjunctive model is crucial for safety and efficacy, emphasizing that any change to a pet’s epilepsy regimen must be veterinarian-guided.
3. **The Non-Negotiable: Veterinary Partnership and Monitoring.** The finding on ALP levels is a vital takeaway. Administering CBD, especially to a pet on other medications, **must** be done under veterinary supervision with periodic blood tests to monitor liver enzymes. This ensures the therapy helps the brain without harming the liver.
4. **Hope for Refractory Cases:** For owners of dogs where every other option seems exhausted, this study offers a new avenue for hope grounded in scientific methodology, not just anecdote.

—

### **Practical Applications: Bridging Research to Reality**

For pet owners exploring CBD, this research provides a roadmap:
* **Consult Your Veterinarian First:** Always begin with a full neurological workup and discussion with your vet. Rule out other causes of seizures and establish a current baseline for seizure frequency and bloodwork.
* **Source Quality Matters:** The study used a specific, standardized veterinary CBD product. Use only high-quality, full-spectrum products from reputable companies that provide Certificates of Analysis (CoAs) confirming potency and purity (free of THC, pesticides, and heavy metals).
* **Embrace the “Start Low, Go Slow” Mindset:** Initiate therapy at a dose far lower than product labels might suggest. The Kasetsart model suggests starting at approximately 0.৫ mg/kg BID. Maintain each dose level for at least two weeks, monitoring for both efficacy (seizure reduction) and tolerance (no lethargy or upset stomach).
* **Maintain a Seizure Diary:** Objective data is irreplaceable. Log every seizure (date, time, duration, type), cluster incidents, any potential side effects. This information is invaluable for your vet to assess response and guide titration.
* **Schedule Follow-up Bloodwork:** Proactive monitoring is the cornerstone of safety. Your veterinarian will likely recommend baseline bloodwork and follow-up panels, particularly tracking liver enzymes like ALP.

This pioneering study from Thailand has successfully bridged a critical gap between anecdotal hope and veterinary science. By providing a structured, cautious, and monitor-based framework, it empowers veterinarians and pet owners to harness the potential of CBD not as a mere supplement, but as a legitimate, evidence-informed adjunctive therapy in the compassionate fight against canine epilepsy. The future of this treatment looks bright, contingent upon continued research and the steadfast application of meticulous, individualized patient care.

**Sources:**
https://pubmed.ncbi.nlm.nih.gov/41463899/
https://pubmed.ncbi.nlm.nih.gov/41389569/
https://pubmed.ncbi.nlm.nih.gov/40968477/